UY39342A - POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER - Google Patents

POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER

Info

Publication number
UY39342A
UY39342A UY0001039342A UY39342A UY39342A UY 39342 A UY39342 A UY 39342A UY 0001039342 A UY0001039342 A UY 0001039342A UY 39342 A UY39342 A UY 39342A UY 39342 A UY39342 A UY 39342A
Authority
UY
Uruguay
Prior art keywords
poziotinib
therapy
lung cancer
small cell
cell lung
Prior art date
Application number
UY0001039342A
Other languages
Spanish (es)
Inventor
Gajanan Bhat
Francois Lebel
Sribalaji Lakshmikanthan
A Barrett John
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of UY39342A publication Critical patent/UY39342A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Se proporciona un método para tratar NSCLC en un sujeto. El método generalmente incluye administrar una cantidad terapéuticamente eficaz de poziotinib o una sal farmacéuticamente aceptable del mismo a un sujeto que lo necesite. El poziotinib exhibe eficacias mejoradas en sujetos con ciertas mutaciones del exón 20 de EGFR o HER2, que dan como resultado resistencia a los inhibidores de tirosina quinasa convencionales.A method of treating NSCLC in a subject is provided. The method generally includes administering a therapeutically effective amount of poziotinib or a pharmaceutically acceptable salt thereof to a subject in need thereof. Poziotinib exhibits enhanced efficacies in subjects with certain EGFR or HER2 exon 20 mutations, which result in resistance to conventional tyrosine kinase inhibitors.

UY0001039342A 2020-07-27 2021-07-27 POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER UY39342A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063056895P 2020-07-27 2020-07-27
US202063199446P 2020-12-29 2020-12-29
US202163155123P 2021-03-01 2021-03-01
US202163166722P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
UY39342A true UY39342A (en) 2022-02-25

Family

ID=80036135

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039342A UY39342A (en) 2020-07-27 2021-07-27 POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER

Country Status (3)

Country Link
TW (1) TW202211923A (en)
UY (1) UY39342A (en)
WO (1) WO2022026442A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39593A (en) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc TREATMENT FOR MALIGNANT SOLID TUMORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2841600T3 (en) * 2015-10-19 2021-07-08 Sunshine Lake Pharma Co Ltd Di (methanesulfonic acid) salt of (3-chloro-4-fluoro-phenyl) - (6 - ((4aR, 7aS) -3- (hexahydro- (1,4) dioxino (2,3-c) pyrrole- 6-yl) -propoxy) -7-methoxy-quinazolin-4-yl) -amine and crystalline form of the monohydrate (an EGFR inhibitor)
EP3541832A4 (en) * 2016-11-17 2020-09-30 Board of Regents, The University of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
MX2020012540A (en) * 2018-05-23 2021-02-16 Jiangsu Hengrui Medicine Co Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases.
WO2020052575A1 (en) * 2018-09-12 2020-03-19 江苏恒瑞医药股份有限公司 Use of combination of jak kinase inhibitor and egfr inhibitor in preparation of medicament for treating tumor diseases

Also Published As

Publication number Publication date
TW202211923A (en) 2022-04-01
WO2022026442A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
ECSP19043254A (en) COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS THAT HAVE MUTATIONS IN EXON 20 OF EGFR OR HER2
MX2020009773A (en) Combination therapy.
MX2021005651A (en) Pharmaceutical combination for treatment of cancer.
BR112015026095A2 (en) methods for controlling the dosage of an antitumor drug administered to a cancer patient, for administering at least one antitumor drug in two separate doses in a cancer patient and for selecting at least one antitumor drug
AR095197A1 (en) COMBINATION OF AN EGFR T790M INHIBITOR AND EGFR INHIBITOR FOR THE TREATMENT OF PULMONARY CANCER OF NON-SMALL CELLS
TW201613589A (en) Combination methods for treating cancers
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
BR112021006318A2 (en) combination therapy for cancer treatment
MX2020001727A (en) Combination therapy.
UY39342A (en) POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER
PH12021551276A1 (en) Combination therapy for the treatment of cancer
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
BR112022000382A2 (en) Administration of sting agonists and checkpoint inhibitors
CL2022002682A1 (en) Co-administration of mirdametinib and lifirafenib for use in the treatment of cancers
MX2021012705A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations.
AR049135A1 (en) COMPOSITION, METHOD, KIT AND TREATMENT WITH OXALIPLATIN AND AN EGFR INHIBITOR, AS ERLOTINIB
CL2020000270A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor.
CL2022000781A1 (en) Medicinal cognitive treatments
AR123058A1 (en) POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER
BR112022009470A2 (en) DAILY TREATMENT SCHEME FOR CANCER WITH A PRMT5 INHIBITOR
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
MX2021001764A (en) Combination therapy.
MX2021009637A (en) Combination therapies for use in treating cancer.
Maraver et al. Notching up a new therapeutic strategy for non-small cell lung carcinoma (NSCLC)
BR112022003286A2 (en) Combination of poziotinib with vegfr2 inhibitors and methods of using it